Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma

Ahmed O. Kaseb1*, Abdul Haque2, Deeksha Vishwamitra2, Manal M. Hassan3, Lianchun Xiao4, Bhawana George2, Vishal Sahu2, Yehia I. Mohamed1, Roberto Carmagnani Pestana1, Jamie Lynne Lombardo5, Rony Avritscher6, James C. Yao1, Robert A. Wolff1, Asif Rashid5, Jeffrey S. Morris4† and Hesham M. Amin2,7*

1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 3Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 5Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 6Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 7MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, United States

Hepatocellular carcinoma (HCC) is an aggressive neoplasm with poor clinical outcome because most patients present at an advanced stage, at which point curative surgical options, such as tumor excision or liver transplantation, are not feasible. Therefore, the majority of HCC patients require systemic therapy. Nonetheless, the currently approved systemic therapies have limited effects, particularly in patients with advanced and resistant disease. Hence, there is a critical need to identify new molecular targets and effective systemic therapies to improve HCC outcome. The liver is a major target of the growth hormone receptor (GHR) signaling, and accumulating evidence suggests that GHR signaling plays an important role in HCC pathogenesis. We tested the hypothesis that GHR could represent a potential therapeutic target in this aggressive neoplasm. We measured GH levels in 767 HCC patients and 200 healthy controls, and then carried out clinicopathological correlation analyses. Moreover, specific inhibition of GHR was performed in vitro using siRNA and pegvisomant (a small peptide that blocks GHR signaling and is currently approved by the FDA to treat acromegaly) and in vivo, also using pegvisomant. GH was significantly elevated in 49.5% of HCC patients, and these patients had a more aggressive disease and poorer clinical outcome (P<0.0001). Blockade of GHR signaling with siRNA or pegvisomant induced substantial inhibitory cellular effects in vitro. In addition, pegvisomant potentiated the effects of sorafenib (P<0.01) and overcame sorafenib
Introduction

Hepatocellular carcinoma (HCC) is an aggressive neoplasm associated with poor clinical outcome and, therefore, is considered a major health problem worldwide (1). Since the early 1980s, the incidence of HCC has tripled in the US, and it is currently the fastest growing cause of cancer-related mortality. This is because up to 80% of HCC patients are diagnosed at an advanced stage with underlying cirrhosis and/or fibrosis, which precludes curative treatment options such as surgical resection and liver transplantation (2).

Systemic treatment options for HCC are limited. Sorafenib, an orally available tyrosine kinase inhibitor (TKI), demonstrated a modest but significant overall survival (OS) benefit as compared to placebo (10.7 vs. 7.9 months, hazard ratio (HR) 0.69; P<0.001) (3). Additional TKI including lenvatinib, regorafenib, ramucirumab, and cabozantinib also demonstrated slight OS improvements ranging from 1.6 to 2.8 months vs. placebo (4–7). Immune checkpoint blockade was also evaluated in HCC. Phase I/II studies showed modest effects of the anti-PD-1 antibodies nivolumab and pembrolizumab as single therapies in HCC patients who progressed on sorafenib (8, 9). Most recently, the FDA approved the combination of atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) as first-line therapy, based on phase III IMbrave150 trial, which assessed this combination vs. sorafenib and yielded longer progression-free survival (PFS) of 6.8 vs. 4.3 months, HR 0.59; P<0.001, and objective response rate of 27% vs. 12% (10).

However, more recent studies suggest that immune checkpoint blockade may not be effective in HCC when associated with non-alcoholic steatohepatitis and hepatic fibrosis (11–13). Therefore, progress is needed and effective systemic therapies against HCC remain an unmet need.

The growth hormone (GH) receptor (GHR) is a prototype class I cytokine receptor, and the liver is considered a key organ in GHR signaling (14). Recently, the contribution of GHR signaling to the development, survival, and progression of cancer has gained increasing attention (15). Notably, patients with Laron syndrome, who have GHR gene deficiency, rarely develop cancer (16). Conversely, in a population-based study, patients treated with human pituitary GH were found to have a significantly higher risk of dying from cancer (17). It is believed that in cancer cells, binding of GH with GHR activates receptor associated intracellular domain such as JAK2, which further accelerate activation of oncogenic transcription factors STAT3 and STAT5, and other survival molecules including IRS-1, AKT, and ERK (18–20).

Previous preclinical and clinical observations suggest that GHR/GH signaling plays an important role in HCC pathogenesis (18, 21–28). However, a major gap still exists in current understanding of the relevance of this pathway to HCC and none of these observations has been translated into a clinical trial strategy to block GHR signaling in HCC patients. Our working hypothesis and proposed model (Figure 1) are that chronic liver disease and liver tissue insult decrease hepatic production of circulating IGF-I in HCC patients (28–30). Subsequently such a decrease leads to increased pituitary secretion of GH via loss of negative feedback from IGF-I. In turn, increased GH enhances the activation of GHR. These molecular events support the survival and progression of HCC and, therefore, counteracting these events by targeting GHR, e.g., by pegvisomant, may lead to antitumor effects. Of note is that pegvisomant is a small peptide that blocks the binding and interactions between GHR and GH and is currently used to treat acromegaly patients who suffer increased GH secretion and hyperactivity of GHR. To achieve our goals, we measured circulating GH levels in a large cohort of HCC patients and normal controls, and correlated the results with response to therapy and patients’ survival. We also studied the effects of specific antagonism of GHR signaling in vitro by using siRNA and pegvisomant. Moreover, we studied the effects of pegvisomant in vivo using parental and sorafenib-resistant resistance (P<0.0001) in vivo. Mechanistically, pegvisomant decreased the phosphorylation of GHR downstream survival proteins including JAK2, STAT3, STAT5, IRS-1, AKT, ERK, and IGF-IR. In two patients with advanced-stage HCC and high GH who developed sorafenib resistance, pegvisomant caused tumor stability. Our data show that GHR signaling represents a novel “druggable” target, and pegvisomant may function as an effective systemic therapy in HCC. Our findings could also lead to testing GHR inhibition in other aggressive cancers.

KEYWORDS
hepatocellular carcinoma, growth hormone receptor, pegvisomant, targeted therapy, somavert
HCC cells. Finally, we treated two patients with advanced HCC and elevated circulating GH, who developed tumor growth and resistance to sorafenib, with pegvisomant. Our results show that GH/GHR signaling pathway plays important roles in HCC pathogenesis and suggest that exploiting this pathway may represent a successful therapeutic strategy for this aggressive neoplasm.

Materials and methods

Reagents

Human recombinant growth hormone (hrGH) was obtained from R&D Systems (catalogue number: 1067-GH-025; Minneapolis, MN). GHR siRNA was purchased from Santa Cruz Biotechnology (sc-40015; Santa Cruz, CA). Pegvisomant (B2036-PEG, Somavert; Pfizer, New York, NY) was dissolved in sterilized water and stored at -20°C until used. Sorafenib (Nexavar; Bayer, Whippany, NJ) stock solution (8×) was prepared by dissolving sorafenib powder in solution containing cremophor (MilliporeSigma, St. Louis, MO) and ethanol (1:1), with DMSO at <0.3% of the final volume. The stock solution was diluted with sterilized distilled water to 1× solution before being administered to the mice.

Antibodies

The GHR antibodies were purchased from Santa Cruz Biotechnology (sc-137185) and Bioss Antibody (bs-0654R; Woburn, MA); the pAK2 Y1007/Y1008 (3771), JAK2 (3230), pSTAT3 Y705 (4113), STAT3 (9314), STAT5 (9363), pIRS-1 S639 (2388), IRS-1 (2382), pAKT S473 (4051), pERK1/2 T202/Y204 (4370), c-Myc (5605), and Ki-67 (9027) antibodies were purchased from Cell Signaling Technology (Danvers, MA); BCL-xS/L (sc-1041), and MCL-1 (sc-819) were purchased from Santa Cruz Biotechnology; pIGF-IR Y1161 (ab39398) was purchased from AbCam (Cambridge, MA); and β-actin (A2228) was purchased from MilliporeSigma.

Cell lines and normal human liver cells

The cell lines HepG2, SNU-387, SNU-423, and SNU-475 were purchased from ATCC (Manassas, VA). HepG2 cells were cultured in DMEM high-glucose medium (MilliporeSigma), and SNU-387, SNU-423, and SNU-475 cells in RPMI-1640 (MilliporeSigma). Culture media were supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin. Cells were grown at 37°C in 5% CO2. Normal human liver cells (ABM-T0051; Applied Biological Materials, Richmond, BC, Canada) were stored...
at -80°C. Before use, the liver cells were quickly thawed in a 37°C water bath. The resulting cell suspension was transferred into cold culture medium (Hepatocyte Culture Medium BulletKit [CC-3198]; Lonza, Walkersville, MD) and then centrifuged at 150 g for 5 minutes at 4°C. Thereafter, the cell pellet was suspended in hepatocyte culture medium.

Sorafenib-resistant HepG2 cells

Parental HepG2 cells were cultured in increasing concentrations of sorafenib in a humidified incubator at 37°C in 5% CO2. To determine the IC_{50}, cell viability was measured by using the MTS assay. HepG2 cells were then cultured with sorafenib at a concentration just below the IC_{50}. Sorafenib concentration was gradually increased by 0.25 µM/L per week. After 16-20 weeks, sorafenib resistance was assessed by comparing the cell viability of HepG2-SR cells with that of HepG2 cells. HepG2-SR cells were maintained in DMEM high-glucose medium supplemented with 5.0 µM sorafenib.

Cell viability

Cells were seeded in 96-well cell culture plates and incubated overnight before serum starvation for 24 hours. Cells were then treated with hrGH (1.0 µg/mL) with or without pegvisomant. To measure the viability of the cells, 20 µL of the MTS reagent 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (Promega, Madison, WI) was added to each well and cells were incubated for 1 hour at 37°C in 5% CO2. Absorbance at 490 nm was detected using a plate reader (CLARIOstar; BMG Labtech, Cary, NC).

Cell proliferation

A standard kit (X1327K1; Exalpha Biologicals, Shirley, MD) was used to measure cell proliferation. Briefly, cells were incubated for 24 hours in 20 µL of BrdU (1:500). Then, 100 µL of anti-BrdU antibody was added for 1 hour, followed by 100 µL of peroxidase goat anti-mouse IgG conjugate (1:2000) for 30 minutes and 100 µL of TMB substrate for another 30 minutes. Fifty microliters of stop solution was added to stop the reaction, and absorbance was measured at 450/595 nm.

Cell adhesion

Adhesion assays were performed in 12-well plates coated with extracellular matrix gel from Engelbreth-Holm-Swarm murine sarcoma cells (ECM Gel [E1270]; MilliporeSigma) diluted 2-fold using appropriate cell culture media. Control cells and cells treated with GHR inhibitor were added to the gel-coated plates and incubated for 72 hours. After incubation, the plates were washed with phosphate-buffered saline (PBS) to remove the unattached cells. Attached cells were then stained with 0.5% crystal violet for 1 hour at room temperature. After the wells were washed with PBS, the bound cells were evaluated by using bright-field microscopy (magnification: ×25).

Sorafenib-resistant HepG2 cells

Parental HepG2 cells were cultured in increasing concentrations of sorafenib in a humidified incubator at 37°C in 5% CO2. To determine the IC_{50}, cell viability was measured by using the MTS assay. HepG2 cells were then cultured with sorafenib at a concentration just below the IC_{50}. Sorafenib concentration was gradually increased by 0.25 µM/L per week. After 16-20 weeks, sorafenib resistance was assessed by comparing the cell viability of HepG2-SR cells with that of HepG2 cells. HepG2-SR cells were maintained in DMEM high-glucose medium supplemented with 5.0 µM sorafenib.

Cell migration

Cell migration was analyzed using 24-well Corning Transwell plates with polycarbonate membranes (3428; MilliporeSigma). Briefly, control cells or cells treated with GHR inhibitor in serum-free culture medium were loaded into the upper compartment and serum-free culture medium with 1.0 µg/mL hrGH was simultaneously loaded into the lower compartment. The plates were incubated for 4 hours at 37°C, and a particle counter and size analyzer (Beckman Coulter, Brea, CA) was used to count the cells that migrated through the membrane into the lower chamber.

Anchorage-independent colony formation

Cells were plated in methylcellulose-based medium (Methcoul H4230; Stemcell Technologies, Vancouver, BC, Canada) mixed with DMEM or RPMI-1640 (1:5). Thereafter, the cells were harvested, suspended in methylcellulose (1:10), poured into 24-well plates, and incubated for 5 days at 37°C in 5% CO2. Cell colonies were stained using p-iodonitrotetrazolium violet and visualized using the FluorChem 8800 imaging system (Alpha Innotech, San Leandro, CA).

Western blotting

Whole cell lysates were extracted using lysis buffer. Protein concentrations were determined using a protein assay kit (Quick Protein Assay Kit [500-0006]; Bio-Rad, Hercules, CA). Equal amounts of protein were separated using 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Millipore, Burlington, MA). Membranes were incubated with appropriately diluted specific primary antibodies. Protein bands were detected with an enhanced chemiluminescence kit (32106; ThermoFisher Scientific, Waltham, MA).

Immunohistochemistry and immunofluorescence staining

Formalin-fixed and paraffin-embedded tissue sections from the tumor xenografts were subjected to xylene and alcohol
Gradient deparaffinization. Briefly, the sections were washed and then placed in a steamer with 1× target retrieval solution (Dako, Carpinteria, CA) for 25 minutes, allowed to cool for 20 minutes at room temperature, washed, and incubated in 3% H2O2 for 25 minutes to block endogenous peroxidase activity. The sections were then washed three times and incubated for 30 minutes in serum-free blocking solution (Dako) at room temperature. Primary antibodies (Ki-67, 1:400; GHR, 1:100; pAKT^S473, 1:10; pERK1/2^T202/Y204, 1:50; pIGF-IR^Y1161, 1:75) were diluted in blocking buffer and added for overnight incubation at 4°C. Next, the sections were washed three times and incubated with the secondary antibody (K4063; Envision Dual Link HRP System; Dako) for 30 minutes. The slides were washed three times and developed with 3,3′-Diaminobenzidine substrate using the Dako chromogen system (K3468). Hematoxylin and eosin (H&E) were used for counterstaining. To calculate the proliferation index (PI), the Ki-67-positive cells in at least 10 high-power fields (×400) were counted, and the average number of positive cells per 1 high-power field was calculated. The light photomicrographs were captured using an Olympus BX41 microscope (Olympus Scientific Solutions, Waltham, MA), Infinity 3 camera (Teledyne Lumenera, Ottawa, Ontario, Canada), and Infinity Capture software (version 6.3.2., Teledyne Lumenera). The fluorescence photomicrographs were captured using an Olympus IX70 fluorescence microscope (Olympus), Olympus DP72 camera (Olympus), and Aperio ImageScope software (Lecia Biosystems, Deer Park, IL).

**GH levels in HCC patients**

Plasma samples from 767 HCC patients (567 males and 200 females) (489 with underlying cirrhosis and 278 without cirrhosis) admitted to our institution between 2001 and 2014 were analyzed for GH levels using the Rules-Based Medicine (RBM) multiplex ELISA (Myriad RBM, Austin, TX) in a CLIA-certified environment. Plasma from 200 healthy individuals (118 males and 82 females) was used as control.

**In vivo experiments**

Animal experiments were approved by our Institutional Animal Care and Use Committee. Swiss nu/nu/Ncr nude mice (5-6 weeks old) were purchased from the Department of Experimental Radiation Oncology (authorized vendor, The University of Texas MD Anderson Cancer Center, Houston, TX). HepG2 or HepG2-SR cells (5.0 × 10^5) dissolved in PBS and matrigel (1:1 in volume; 354234; Corning Life Sciences, Tewksbury, MA) were subcutaneously injected into the mice’s flanks. Approximately 7 days after inoculation, visible tumor growth was noted. Tumor length and width were measured using digital calipers, and tumor volumes were calculated using the formula: volume = π/6 × length × width^2. When tumor volumes were between 70-90 mm^3, mice were randomly divided into the different groups described in the results. Termination of the experiments was performed after 24 days or when signs of tumor burden developed. After euthanasia, tumors were dissected, weighed, and fixed in 10% buffered formalin for further immunohistochemical analysis. Tumor growth curves were plotted using average tumor volumes within each experimental group at the set time point.

**Enzyme-linked immunosorbent assay**

Prior to euthanasia, blood was collected from the mice by cardiac puncture and then left to clot at room temperature for 30 minutes. Serum was separated by spinning the blood in a cooled Eppendorf centrifuge at 450g for 10 minutes. Serum GH and IGF-I levels were measured using mouse-specific ELISA kits from Biomatik (EKU04609; Wilmington, DE) and R&D Systems (MG100), respectively.

**Pegvisomant treatment of HCC patients**

We treated two male patients with pegvisomant (10 mg/day). The patients had high plasma GH levels and developed clinical resistance to sorafenib leading to progressive disease. Pegvisomant was administered based on an off-label use of the FDA-approved drug owing to the patients’ high plasma GH levels.

**Statistical analysis**

Statistical differences between the experimental groups were measured by using two-way ANOVA or Student’s t-test where appropriate in the in vitro studies and by using one-way ANOVA in the in vivo studies. Prism 8 for MacOS (GraphPad Software, San Diego, CA) was used for statistical analysis. Plasma biomarkers were summarized using descriptive statistics, and categorical clinical variables were tabulated with frequency and percentage. The Kruskal-Wallis test was applied for comparison of biomarkers among groups of healthy controls vs. HCC patients with or without cirrhosis, whereas Wilcoxon rank sum test was used for two-group comparisons including healthy controls vs. HCC, and HCC with cirrhosis vs. HCC without cirrhosis. Chi-square test was used to evaluate the association of GH level (high vs. normal) and categorical clinical factors. OS was estimated using the Kaplan-Meier method and compared using the log rank test. SAS 9.4 (SAS Institute, Cary, NC) and S-PLUS (v8.2; TIBCO Software, Palo Alto, CA) were used for statistical analysis. P<0.05 was considered statistically significant.
Results

High GH levels are associated with poorer clinical outcome in HCC patients

Human studies were performed in accordance with the Declaration of Helsinki and approved by our Institutional Review Board. We measured plasma GH levels in 767 HCC patients (567 males, 200 females) and 200 healthy controls (118 males, 82 females). High GH levels (mean ± SD = 2.98 ± 4.4 µg/L) were found in 49.5% of HCC patients compared with low GH in 50.5% of the patients (0.41 ± 0.96 µg/L) (P<0.0001) (Table 1). High GH levels were associated with advanced disease and poor clinical outcome including more frequent cirrhosis, poorly differentiated tumors, multi-nodularity, vascular invasion, higher α-fetoprotein (AFP) levels, and advanced clinicopathological staging (Table 1). In agreement with our hypothesis and proposed model (Figure 1), patients, irrespective of their gender, with high GH levels had significantly lower circulating IGF-I than patients with low GH levels (P<0.0001) (Table 2). In addition, there was no difference in

| Covariates                  | Low GH 0.69 ± 0.78 | High GH 5.31 ± 5.41 | P values |
|-----------------------------|--------------------|---------------------|----------|
| Gender                      |                    |                     |          |
| Females                     | 154 (39.8%)        | 46 (12.1%)          | < 0.0001 |
| Males                       | 233 (60.2%)        | 334 (87.9%)         |          |
| Underlying cirrhosis        |                    |                     |          |
| No                          | 170 (43.9%)        | 108 (28.4%)         | < 0.0001 |
| Yes                         | 217 (56.1%)        | 272 (71.6%)         |          |
| Severity of underlying cirrhosis |                |                     |          |
| Child-Pugh A                | 248 (64.1%)        | 164 (43.2%)         | < 0.0001 |
| Child-Pugh B                | 131 (33.9%)        | 168 (44.2%)         |          |
| Child-Pugh C                | 8 (2.1%)           | 48 (12.6%)          |          |
| Pathological differentiation |                    |                     |          |
| Poorly differentiated       | 86 (22.2%)         | 102 (26.8%)         | 0.084    |
| Well to moderately differentiated |            | 225 (58.1%)        | 179 (47.1%) |
| Missing                     | 76 (19.6%)         | 99 (26.1%)          |          |
| Tumor nodularity            |                    |                     |          |
| Multinodular                | 216 (55.8%)        | 258 (67.9%)         | 0.0021   |
| Uni-nodular                 | 156 (40.3%)        | 114 (30%)           |          |
| Missing                     | 15 (3.9%)          | 8 (2.1%)            |          |
| Vascular invasion           |                    |                     |          |
| No                          | 301 (77.8%)        | 223 (58.7%)         | < 0.0001 |
| Yes                         | 85 (22%)           | 156 (41.1%)         |          |
| Missing                     | 1 (0.3%)           | 1 (0.3%)            |          |
| Tumor involvement           |                    |                     |          |
| ≤50%                        | 304 (81.9%)        | 258 (69.5%)         | 0.0001   |
| >50%                        | 67 (18.1%)         | 113 (30.5%)         |          |
| AFP (ng/mL)                 |                    |                     |          |
| <400                        | 289 (74.7%)        | 227 (59.7%)         | < 0.0001 |
| ≥400                        | 98 (25.3%)         | 153 (40.3%)         |          |
| CLIP staging                |                    |                     |          |
| Stage 0-2                   | 294 (76%)          | 191 (50.3%)         | < 0.0001 |
| Stage 3                     | 53 (13.7%)         | 94 (24.7%)          |          |
| Stage 4-6                   | 24 (6.2%)          | 85 (22.4%)          |          |
| Missing                     | 16 (4.1%)          | 10 (2.6%)           |          |
| Okuda staging               |                    |                     |          |
| Stage I                     | 243 (62.8%)        | 142 (37.4%)         | < 0.0001 |
| Stage II                    | 123 (31.8%)        | 205 (53.9%)         |          |
| Stage III                   | 5 (1.3%)           | 24 (6.3%)           |          |
| Missing                     | 16 (4.1%)          | 9 (2.4%)            |          |
| TNM staging                 |                    |                     |          |
| Stage I-II                  | 171 (44.2%)        | 82 (21.6%)          | < 0.0001 |
| Stage IIIA                  | 86 (22.2%)         | 139 (36.6%)         |          |
| Stage IIIIC                 | 119 (30.7%)        | 147 (38.7%)         |          |
| Missing                     | 11 (2.8%)          | 12 (3.2%)           |          |
| BCLC staging                |                    |                     |          |
| Stage 0-B                   | 113 (29.2%)        | 59 (15.5%)          | < 0.0001 |
| Stage C-D                   | 268 (69.3%)        | 320 (84.2%)         |          |
| Missing                     | 6 (1.6%)           | 1 (0.3%)            |          |

*Normal GH level in males is ≤0.97 µg/L and in females is ≤3.7 µg/L. Men with GH > 0.97 µg/L and women with GH >3.7 µg/L were grouped as ‘High GH’ group, otherwise grouped as ‘Low GH’ group. GH levels are shown as means ± SD. GH, growth hormone; N, number of patients; AFP, α-fetoprotein; CLIP, Cancer of Liver Italian Program; TNM, tumor size, number of lymph nodes, absence or presence of metastases; BCLC, Barcelona Clinic Liver Cancer. P values compare patients with normal GH levels vs. patients with high GH levels.
IGF-I levels in males vs. females when compared according to the GH levels (Supplementary Table). Importantly, HCC patients with high GH had a shorter OS (median = 7.59 months, 95% confidence interval (CI): 6.34, 9.36) vs. patients with normal levels of GH (22.74 months, 95% CI: 19.52, 27.47) (P<0.0001) (Figure 2A; Table 3). The shorter OS survival of HCC patients with high GH was gender-independent (Figure 2B; Table 3).

**GHR is highly expressed in HCC cell lines and primary tumors from patients**

The association between high GH levels and poorer clinical outcome in HCC patients prompted additional investigation of the role of GH/GHR signaling in this aggressive neoplasm. Western blotting and immunofluorescence staining revealed that the expression of GHR in the HCC cell lines HepG2, SNU-387, SNU-423, and SNU-475 was upregulated compared to its level in normal human liver cells (Figures 3A, B). In addition, the expression of GHR and downstream target proteins including STAT3, STAT5, and IGF-IR was upregulated in primary human HCC tumors compared with the surrounding non-cancerous liver parenchyma and normal liver tissues (Supplementary Figure 1).

**Specific abrogation of GHR signaling by pegvisomant or siRNA induces pronounced inhibitory effects in HCC cell lines**

Pegvisomant is a small peptide that specifically binds GHR and inhibits its binding with and activation by the GH. It was approved by the FDA to treat acromegaly (31, 32). To study the effects of pegvisomant in HCC cells, we cultured HepG2, SNU-387, SNU-423, and SNU-475 cells in FBS free medium, then stimulated these cells with GH in the presence or absence of pegvisomant (abbreviated PEGV in the figures) for 48 h. Compared with control cells stimulated with GH alone, cell lines treated with pegvisomant demonstrated decreased proliferation, adhesion, migration, and anchorage independent colony formation (Figures 4A-D). The effects of pegvisomant were dose-dependent and cells became more sensitive to its effect at the 18 µg/mL concentration. Consistent with its mechanism of action as a competitive blocker of GH binding with GHR, pegvisomant did not affect GHR expression in SNU-423 and SNU-475 cells (Figure 4E). Nonetheless, pegvisomant remarkably decreased the phosphorylation of JAK2, STAT3, STAT5, and IRS-1 (Supplementary Figure 2F). We also used another specific strategy, i.e., GHR siRNA, to further examine the effects of downregulation of GHR in HCC. Compared with scrambled siRNA, treating HepG2, SNU-423, and SNU-475 cells with GHR siRNA induced remarkable decreases in cellular viability, proliferation, adhesion, and migration (Supplementary Figures 2A-D). The effects of GHR siRNA were time-dependent and became more pronounced at 72 hours. Furthermore, transfecting HepG2 and SNU-475 cells with GHR siRNA significantly decreased their anchorage-independent colony formation potential after 5 days (Supplementary Figure 2E). Mechanistically, siRNA-mediated downregulation of GHR decreased the phosphorylation of downstream effectors of GHR signaling including JAK2, STAT3, STAT5, and IRS-1 (Supplementary Figure 2F).

### TABLE 2 Age and IGF-I levels (ng/ml) in HCC patients with low vs. high GH levels.

|                | Low GH* 0.69 ± 0.78 | High GH* 5.31 ± 5.41 | P value |
|----------------|---------------------|-----------------------|---------|
| All patients   | N = 387 (50.5%)     | N = 380 (49.5%)       |         |
| Age            | 62.9 ± 12.6         | 62.1 ± 10.9           | 0.0407  |
|                | 65.0 (21.0 - 91.0)  | 61.0 (27.0 - 88.0)    |         |
| IGF-I          | 59.0 ± 35.4         | 45.57 ± 27.6          | <0.0001 |
|                | 47.9 (17.4 - 202.7) | 38.0 (13.2 - 219.9)   |         |
| Males          | N = 233 (41.1%)     | N = 334 (58.9%)       |         |
| Age            | 63.0 ± 12.8         | 62.3 ± 10.8           | 0.0972  |
|                | 65.0 (21.0 - 91.0)  | 61.0 (27.0 - 88.0)    |         |
| IGF-I          | 56.8 ± 35.3         | 45.8 ± 27.7           | 0.0001  |
|                | 45.2 (17.4 - 202.7) | 38.3 (13.2 - 219.9)   |         |
| Females        | N = 154 (77.0%)     | N = 46 (23.0%)        |         |
| Age            | 62.7 ± 12.4         | 60.5 ± 11.7           | 0.1917  |
|                | 65.0 (21.0 - 87.0)  | 62.0 (34.0 - 82.0)    |         |
| IGF-I          | 62.3 ± 35.4         | 44.3 ± 27.1           | 0.002   |
|                | 52.3 (18.8 - 193.9) | 34.8 (20.4 - 148.2)   |         |

*Normal GH level in males is ≤0.97 µg/L and in females is ≤3.7 µg/L. Men with GH >0.97 µg/L and women with GH >3.7 µg/L were grouped as “High GH” group, otherwise grouped as “Low GH” group. Data are shown as means ± SD. The median and range (in brackets) are shown below the mean of each parameter. The median and range of the GH levels are shown in Supplementary Table 1.

IGF-I, type I insulin-like growth factor; GH, growth hormone; N, number of patients.
HCC patients with high GH levels have shorter OS. The Kaplan-Meier curves of OS according to GH levels demonstrate that 49.5% of HCC patients (380/767) with high GH levels (>0.97 and >3.7 µg/L in males and females, respectively) had a significantly shorter OS compared with patients with normal GH levels (P<0.0001) (A). The shorter OS survival in HCC patients with high GH levels was gender-independent (B).
together, our pegvisomant and GHR siRNA in vitro data suggest that GH/GHR signaling pathway plays important roles in cell survival, growth, migration, and invasion.

Combining pegvisomant and a low dose of sorafenib causes robust HCC tumor suppression in vivo

Next, we examined the effects of PEGV-100 and SOR-10, alone or in combination, on the growth of HepG2 xenograft tumors in nude mice. Tumor volumes were measured every 2 days and plotted against time. Whereas SOR-10 alone failed to induce significant suppression of tumor growth, PEGV-100 alone was capable of inhibiting tumor growth, and combining PEGV-100 with SOR-10 resulted in greater suppression of tumor growth (Figure 5A). We also measured tumor weights at the end of the study and found changes similar to those in tumor volumes (Figure 5B). The suppressive effects of the dual regimen on tumor growth were further illustrated in the form of a significant decrease in the PI as measured by Ki-67 staining. Whereas SOR-10 induced a minimal decrease in the PI, treatment with PEGV-100 was associated with a pronounced reduction (Figure 5C). Nonetheless, combined treatment with PEGV-100 and SOR-10 induced the largest decrease in the PI.

We were also curious to know whether pegvisomant, similar to its effects in acromegaly patients, reduces circulating IGF-I levels in nude mice with HCC xenografts. Indeed, only mice treated with PEGV-100 alone or with PEGV-100 and SOR-10 had a significant decrease in circulating IGF-I levels (Figure 5D).

**TABLE 3 Log rank test to compare OS between HCC patients with high vs. low GH levels** *

| Variables | N | Events | Median OS (95% CI) | OS Rate at 3 years (95% CI) | OS Rate at 5 Years (95% CI) | P value |
|-----------|---|--------|--------------------|-----------------------------|-----------------------------|---------|
| All patients | 766 | 586 | 14.19 (11.96, 16.13) | 0.23 (0.2, 0.27) | 0.15 (0.13, 0.19) | <0.0001 |
| GH H | 380 | 320 | 7.59 (6.34, 9.36) | 0.11 (0.08, 0.16) | 0.06 (0.04, 0.1) | - |
| L | 386 | 266 | 22.74 (19.52, 27.47) | 0.34 (0.29, 0.4) | 0.24 (0.19, 0.29) | - |
| GH/Gender H/Females | 46 | 36 | 6.14 (3.75, 17.58) | 0.14 (0.06, 0.35) | 0.14 (0.06, 0.35) | <0.0001 |
| L/Females | 153 | 108 | 20.53 (18.86, 28.94) | 0.36 (0.29, 0.46) | 0.24 (0.18, 0.33) | - |
| H/Males | 334 | 284 | 7.72 (6.47, 9.43) | 0.11 (0.08, 0.16) | 0.05 (0.03, 0.09) | - |
| L/Males | 233 | 158 | 23.23 (17.48, 28.68) | 0.33 (0.27, 0.4) | 0.24 (0.18, 0.31) | - |

*Normal GH level in males is ≤0.97 µg/L and in females is ≤3.7 µg/L. Men with GH >0.97 µg/L and women with GH >3.7 µg/L were grouped as "High GH" group, otherwise grouped as "Low GH" group.

N, number of patients; GH, growth hormone; H, high; L, low; OS, overall survival; CI, confidence interval.

**FIGURE 3**

Expression of GHR in HCC cell lines. Western blotting (A) and immunofluorescence staining (B) demonstrate the expression of GHR in the cell lines HepG2, SNU-387, SNU-423, and SNU-475. The expression of GHR was markedly more pronounced in HCC cells than in normal human liver cells.
Similar to patients who receive pegvisomant, significant changes in circulating GH levels were not observed in the mice after treatment with PEGV-100 (Figure 5E).

We also studied the effects of SOR-10 and PEGV-100, alone or in combination, by analyzing the xenograft tumor tissues collected at necropsy (Figure 5F). H&E-stained sections from control-treated tumors as well as tumors treated with SOR-10 alone were composed of sheets of tumor cells, whereas PEGV-100-treated tumors had expanded hemorrhagic areas consistent with therapy effects, which became much more pronounced in tumors treated with PEGV-100 and SOR-10. High levels of expression of GHR were documented in the four groups and, as suspected, treatment with PEGV-100 did not affect the basal tumor levels of GHR. However, cells stained with Ki-67 were much less pronounced in mice that received PEGV-100, and this effect was even greater with combined PEGV-100 and SOR-10, providing further evidence that combining PEGV-100 and SOR-10 suppresses tumor growth more than either of the two therapies alone. Similar effects were noted for pAKT, pERK, and pIGF-IR. Treatment with SOR-10 alone had almost no effect on the expression of these proteins. In contrast, there was a moderate decrease in expression after treatment with PEGV-100, which became much more pronounced when PEGV-100 and SOR-10 were combined.

**Pegvisomant overcomes sorafenib resistance in vivo**

Resistance to sorafenib is commonly encountered in HCC patients and is considered a major hurdle for its utilization in the clinic. We set to study whether pegvisomant is capable of potentiating sorafenib effects and overcoming its resistance. We developed sorafenib-resistant HepG2 cells (HepG2-SR) in which sorafenib IC₅₀ doubled from 6.25 µM in parental HepG2 cells to 12.5 µM in HepG2-SR cells (Supplementary Figure 3A). Biochemical alterations consistent with cell survival, proliferation, and apoptosis resistance were observed in the HepG2-SR cells, including upregulation of the antiapoptotic proteins BCL-xL and MCL-1, and the survival promoting proteins pAKT, pERK, and c-Myc, and downregulation of the proapoptotic protein BCL-xS (Supplementary Figure 3B). Because of the significant biochemical
changes in Hep-SR cells and their resistance to sorafenib, we elected to increase the dose of pegvisomant to 200 mg/kg/day (PEGV-200) in this set of experiments.

We used the HepG2-SR cells and the parental HepG2 cells, in parallel as a biological control, to develop tumor xenografts in nude mice. In parental HepG2 cells, sorafenib at a concentration of 5 mg/kg/day (SOR-5) slightly reduced tumors volumes (Figure 6A) and weights (Figure 6C). Of important note, the addition of pegvisomant PEGV-200 significantly increased the effects of SOR-5 (Figures 6A, C). Whereas in HepG2-SR cells SOR-5 had no inhibitory effect on tumor growth, treatment with PEGV-200 overcame sorafenib resistance and significantly decreased tumors volumes and weights (Figures 6B, D). In addition, treatment with PEGV-200 significantly decreased HCC cell proliferation, measured by Ki-67 proliferation index, in HepG2 and HepG2-SR tumor xenografts (Figures 6E, F). IGF-I is primarily secreted by the liver in response to activation of the GH/GHR signaling. In this study, treatment with PEGV-200, but not SOR-5, was associated with a dramatic decrease in circulating IGF-I levels in both HepG2 and HepG2-SR tumor bearing mice (Figures 6G, H). However, changes in GH levels did not associate the treatment with SOR-5 or SOR-5 +PEGV-200 (Figures 6I, J). We also found that the ability of PEGV-
In vivo effects of antagonizing the GH/GHR signaling axis using pegvisomant in mice with sorafenib-resistant HCC xenografts. We studied the effects of SOR-5 alone vs. SOR-5+PEGV-200 in parental HepG2 tumor xenografts (left panel: five males, five females in the control group; four males, six females in the SOR-5 group; and five males, six females in the SOR-5+PEGV-200 group), and in the HepG2-SR tumor xenografts (right panel: five males, five females in the control group; three males, six females in the SOR-5 group; and six males, six females in the SOR-5+PEGV-200 group). In the parental HepG2 tumors, SOR-5 induced a slight decrease in tumor growth that was not statistically significant (A), whereas in the sorafenib-resistant HepG2-SR tumors it failed to induce any suppression in tumor growth (B). In contrast, treatment with PEGV-200 successfully suppressed the growth of these tumors (A) \( *P = 0.02 \) vs. SOR-5; \( \dagger P < 0.01 \) vs. control, (B) \( *P < 0.0001 \) vs. control and SOR-5. Similar effects were noted on the tumor weights (C) \( *P = 0.01 \) vs. SOR-5; \( P < 0.01 \) vs. control, (D) \( *P < 0.001 \) vs. control and SOR-5). Notably, SOR-5 alone didn’t decrease the proliferation of parental HepG2 tumor xenografts, whereas the addition of PEGV-200 induced a significant decrease in the proliferation of these tumors (E, F) \( *P < 0.0001 \) compared to control and SOR-5. In addition, only mice given PEGV-200 developed a marked decrease in circulating IGF-I levels (G, H) \( *P < 0.0001 \) vs. control and SOR-5). Treatment did not affect the levels of circulating GH (I, J).
200 to overcome sorafenib resistance was gender-independent because its effects on inhibiting tumor growth were similar in male and female mice (Supplementary Figures 3C-F).

The effects of pegvisomant were also studied in HepG2 (Supplementary Figure 4, left panel) and HepG2-SR (Supplementary Figure 4, right panel) tumor xenografts. H&E staining showed that control tumors as well as tumors treated with SOR-5 alone were composed of sheets of viable tumor cells. In contrast, treatment with PEGV-200 was associated with hemorrhagic areas and extensive tumor lysis consistent with therapeutic effects. High levels of GHR expression were seen in the HepG2 and HepG2-SR tumors; however, staining for Ki-67 illustrated that PEGV-200 significantly decreased the proliferation of the neoplastic cells. In addition, the administration of PEGV-200 dramatically downregulated the expressions of pAKT, pERK, and pLGFR in HepG2 and HepG2-SR tumor tissues, which became primarily localized in residual small clusters of tumor cells (Supplementary Figure 4).

**Pegvisomant induces tumor stability in HCC patients with clinical resistance to sorafenib**

Our in vitro and in vivo preclinical data suggest that targeting GH/GHR by using pegvisomant might represent a promising approach to treat HCC patients. Therefore, we treated two HCC patients who had high plasma GH levels with pegvisomant combined with sorafenib following clinical resistance and progression on sorafenib alone. Patient 1 was a 61-year-old white man with a history of alcoholic cirrhosis who had a large left liver HCC mass associated with left portal vein tumor thrombus (PVTT). This patient was treated with sorafenib. After 10 weeks, his AFP level had significantly increased, and imaging showed a new right PVTT. The patient’s GH levels were also elevated (5.3 µg/L), making him eligible for off-label administration of pegvisomant. Thus, pegvisomant (10 mg/day) was added to sorafenib at the time of progression. Patient 2 was a 54-year-old Hispanic man with hepatitis C-related cirrhosis and multifocal HCC who was also treated with sorafenib. He developed a new left PVTT about 6 months after sorafenib initiation and his AFP level was mildly elevated. Pegvisomant (10 mg/day) was added to sorafenib at the time of progression when he was found to have a high GH level (3.7 µg/L). Magnetic resonance imaging scans of the two patients showed PVTT thrombi prior to starting pegvisomant (Figure 7, left panel), and the same lesions stabilized upon administration of pegvisomant (after 6 weeks in patient 1 and 7 weeks in patient 2) (Figure 7, right panel). In addition to tumor stability, the administration of pegvisomant was associated with a 40% reduction in AFP levels in patient 1, while these levels remained stable in patient 2.

**Discussion**

In this paper, we report that GH levels were significantly elevated in 49.5% of plasma samples from 767 HCC patients and that the elevated GH was associated with poorer clinical outcomes and advanced clinicopathological features including high AFP levels, underlying cirrhosis, multi-nodularity, and vascular invasion, as well as with advanced tumor size, number of lymph nodes, and presence of metastases (TNM) and Barcelona Clinic Liver Cancer (BCLC) staging systems. The association of high GH levels with poorer clinical outcomes was gender-independent, despite the notably higher physiological levels of circulating GH in women compared with men (normal GH level in women: ≤3.7 µg/L and in men: ≤0.97 µg/L). We also found that GHR is commonly overexpressed in HCC cell lines and in human tumors. Thereafter, we used pegvisomant to induce in vitro specific blockade of the GH/GHR binding and interaction, which resulted in decreased cell proliferation, adhesion, migration, and anchorage-independent colony formation of these cells, and mechanistically downregulated the phosphorylation of important downstream effectors of GHR, including JAK2, STAT3, STAT5, and IRS-1. The contribution of GHR signaling to the survival of HCC cells was further demonstrated when siRNA was used to specifically abrogate the expression of GHR. In the in vitro experiments we used cell lines with epithelial (HepG2) and mesenchymal (SNU-387, SNU-423, and SNU-475) phenotype. Pegvisomant and GHR siRNA induced significant inhibitory effects in these cell lines regardless of their phenotype background. Our in vivo experiments in nude mice showed that pegvisomant potentiated the effects of sorafenib and overcame sorafenib resistance in parental and sorafenib-resistant tumor xenografts, respectively. Pegvisomant decreased tumor growth in mice and significantly reduced tumor cell proliferation. Mechanistically, pegvisomant decreased the phosphorylation of ERK, AKT, and IGF-IR; downstream modulators of GH/GHR signaling that serve as survival proteins in HCC.

HCC is an aggressive malignancy with poor outcomes and limited curative treatment options for advanced-stage disease. The association between GH/GHR signaling and liver cell proliferation and the development of HCC has been previously demonstrated in different animal models. For instance, in GH-deficient dwarf rats, GH administration increases liver expression of genes that promote cell proliferation and survival, such as STAT3 and MAP kinase (33). Similarly, Ghs transgenic mice suffer a remarkable increase in liver cell proliferation that leads to HCC, which has been attributed to higher GHR levels and increased expression and phosphorylation of survival-promoting targets including STAT3, ERK, AKT, EGFR, Src, and mTOR (21, 34, 35). Moreover, diethylaminoethyl-induced HCC was more frequently observed in Ghs transgenic mice than in wild-type...
mice (22). Studies from different groups also demonstrated that GH/GHR signaling stimulates the proliferation of HCC cells in vitro and the growth of HCC tumor xenografts in nude mice (23–25). Recently, we demonstrated that downregulation of GHR expression hinders HCC development and decreases its tumor burden in mice with disrupted Ghr gene expression (26).

In addition to animal-based evidence, previous studies also showed that GHR is highly expressed in human HCC tumors (27). In the current study, we demonstrated for the first time that specific blockade of GH/GHR signaling pathway using pegvisomant, an FDA-approved drug, potentiates the effects of sorafenib and overcomes its resistance in nude mice xenograft tumors as well as in two HCC patients who developed resistance and progressed on sorafenib. Collectively, these data suggest that GH/GHR signaling contributes to HCC pathogenesis and, therefore, that targeting GHR could be considered a potential approach to eradicate this aggressive neoplasm.

Pegvisomant is a genetically modified human GH analogue with several mutated amino acids (36). As a result, it binds to GHR dimer but does not induce the conformational changes required for signaling (37). Pegvisomant has been approved by the FDA to treat acromegaly, a clinicopathological state of elevated GH levels (31, 32). It is a highly specific drug because it does not cross-react with other structurally related receptors such as the prolactin receptor (38). Analyzing the pharmacodynamic characteristics of pegvisomant showed that up to 80 mg/day was tolerable with minimal adverse effects (39). Thus, the use of pegvisomant in HCC is advantageous because it is tolerable even at doses significantly higher than the 10 mg/day that we used in our patients, which could further enhance its anti-tumor activity. A few preclinical studies have investigated pegvisomant in malignant neoplasms and showed that it has promising effects in cancers of the colon, breast, and endometrium and in meningiomas (40–43). However,
Our data present evidence that such an approach is feasible and applicable to routine practice. Of important note is that pegvisomant could also be combined with tyrosine kinase inhibitors or immunotherapy drugs that have been approved for HCC treatment, yet have limited effects.

When liver functions and reserve are normal, pegvisomant-mediated blockade of GH/GHR signaling results in decreased serum concentrations of total and free IGF-I, a growth-promoting cytokine in acromegaly and a survival-promoting cytokine for cancer cells, in humans (39). Similarly, we observed a remarkable decrease in circulating IGF-I levels in mice treated with pegvisomant. Unlike our nude mice with subcutaneously implanted HCC xenografts who maintain intact livers capable of secreting physiologic levels of IGF-I, patients with HCC encounter deterioration in liver reserve and function during disease progression, which leads to significant reduction in circulating IGF-I (28–30). In line with these observations, our current results show that IGF-I levels are significantly decreased in HCC patients who have high GH levels, owing to the loss of the negative feedback effect of IGF-I on GH secretion by the pituitary. Notably, patients with high GH/low IGF-I suffer a more advanced and aggressive disease and exhibit shorter OS. It is possible that IGF-I contributes to the survival of HCC during early stages. However, this effect wanes with disease progression, whereas GH/GHR signaling enhances to further promote the survival and progression of HCC. Additional studies are required to further explore this model.

In conclusion, our study tested and validated for the first time the concept of inhibiting GHR/GH signaling in HCC by using pegvisomant, a drug that is already FDA approved, at multiple levels including in vitro and in vivo preclinical experiments as well as a pilot human study that demonstrated activity in sorafenib-resistant settings. Altogether, the results support our hypothesis and proposed model shown in Figure 1. While we are aware that our therapeutic studies in patients represent a limited experience, these studies are relevant because they show potential clinical efficacy that warrants further investigation in future large, randomized, clinical trials by integrating pegvisomant into front- and second-line settings in HCC patients with high GH levels. We also anticipate that such an approach is advantageous and feasible given that approximately half of HCC patients have elevated GH levels and, therefore, could be eligible for pegvisomant treatment. Our findings may also lead to future studies exploring the targeting of GHR signaling in other aggressive neoplasms.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human patients/participants were reviewed and approved by Institutional Review Board, The University of Texas MD Anderson Cancer Center. The patients/participants provided their written informed consent to participate in this study. The animal studies were reviewed and approved by Institutional Animal Care and Use Committee (IACUC), The University of Texas MD Anderson Cancer Center.

Author contributions

AK and HA: conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, validation, investigation, visualization, methodology, writing-original draft, project administration, and writing-review and editing. AH: data curation, formal analysis, validation, investigation, methodology, and writing-original draft. DV and BG: data curation, formal analysis, validation, investigation, and methodology. MH: resources, data curation, and formal analysis. LX and JM: formal analysis, validation, and methodology. VS, YM, RCP, JL, and RA: formal analysis and validation. JY, RW, and AR: resources and formal analysis. All authors contributed to the article and approved the submitted version.

Funding

All of the authors declare no competing financial interests related to this work. This work was supported in part by the National Institutes of Health/National Cancer Institute grants R01CA151533 (HA), R21CA170035 (AK), R21CA190945 (AK), R01CA260872 (AK, HA), and by an MD Anderson Cancer Center Bridge Funding Grant (HA).

Acknowledgments

We thank Ms. Dawn Chalaire for outstanding assistance with editing our manuscript, and Mr. Jordan Pietz for excellent help with generating Figure 1. Humanized pegvisomant was generously provided at no cost by Pfizer (New York, NY) for the mice experiments.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.986305/full#supplementary-material

SUPPLEMENTARY TABLE 1

Age and IGF-1 levels (ng/ml) in male vs. female HCC patients.

| Age Group | Male (n=10) | Female (n=6) | P-value |
|-----------|------------|-------------|---------|
| 20-30     | 6.2 ± 2.1  | 4.7 ± 1.8   | 0.05    |
| 31-40     | 7.8 ± 2.5  | 5.5 ± 2.0   | 0.03    |
| 41-50     | 8.9 ± 2.9  | 6.3 ± 2.5   | 0.02    |
| 51-60     | 10.4 ± 3.2 | 7.8 ± 2.9   | 0.01    |
| >60       | 12.0 ± 3.9 | 9.2 ± 3.5   | 0.001   |

SUPPLEMENTARY FIGURE 1

Expression of GHR in HCC primary human tumor tissues. Immunohistochemical staining was performed using primary HCC tumor samples from patients (9 males and three females). Both HCC tumors and the surrounding non-cancerous tissues (NCT) were stained. GHR was highly expressed in 10 (93.3%) out of 12 tumors. The expression of survival proteins that are known to interact with GHR, including STAT3, STAT5, and IGF-IR, was more pronounced in the HCC areas than in the surrounding NCT. Representative examples from two different tumors are shown in (A). Weak expression of GHR, STAT3, STAT5, and IGF-IR was present in normal liver tissues. Three normal liver tissue samples are shown in (B). Original magnification is x400.

SUPPLEMENTARY FIGURE 2

Effects of specific downregulation of GHR by siRNA. HCC cell lines were transfected with scrambled siRNA or with GHR siRNA for 48 and 72 h. Compared with scrambled siRNA, GHR siRNA induced significant decrease in cell viability (A) \( P < 0.0001 \) vs. scrambled siRNA; \( P < 0.05 \) vs. GHR siRNA (72 h). \( P > 0.01 \) vs. scrambled siRNA, proliferation (B) \( P < 0.0001 \) vs. other conditions; \( P < 0.001 \) vs. scrambled siRNA, \( P < 0.0001 \) vs. scrambled siRNA, \( P < 0.001 \) vs. GHR siRNA (48 h), adhesion (C) \( P < 0.0001 \) vs. scrambled siRNA, \( P < 0.01 \) vs. GHR siRNA (72 h), migration (D) \( P < 0.0001 \) vs. other conditions. GHR siRNA also decreased the anchorage-independent colony formation in HepG2 and SNU-475 cells (E) \( P < 0.05 \) and \( P < 0.01 \) vs. scrambled siRNA. The results are shown as means ± SE. Transfection of GHR siRNA in HepG2, SNU-423, and SNU-475 cells decreased levels of GHR-interacting proteins pAKT, pSTAT3, pSTAT5, and pIRS-1 (F).

SUPPLEMENTARY FIGURE 3

The effects of pegvisomant on sorafenib-resistant HepG2 (HepG2-SR) xenografts are gender-independent. We used parental HepG2 cells to develop sorafenib-resistant counterparts (HepG2-SR). Cell viability assay shows that the IC50 for sorafenib doubled from 6.25 µM in parental HepG2 cells to 12.50 µM in HepG2-SR cells (A). Despite that the development of sorafenib resistance in HepG2-SR cells was not associated with changes in GHR levels, sorafenib resistance was associated with pronounced alterations that favor cell survival including upregulation of BCL-xl and MCL-1 and downregulation of BCL-xS. Moreover, sorafenib resistance was associated with increased pAKT, pERK, and c-Myc (B). We also found that the ability of PEGV-200 to overcome sorafenib resistance is gender independent because tumor growth and weight were similar in males (5 mice) and females (6 mice). In males: \( \ast P < 0.001 \) vs. control and SOR-5 for tumor growth (C) and \( \ast P < 0.01 \) vs. control and SOR-5 for tumor weight (D). In females: \( \ast P < 0.01 \) vs. control and SOR-5 for tumor growth (E) and tumor weight (F).

SUPPLEMENTARY FIGURE 4

Pegvisomant overcomes sorafenib resistance and decreases tumor cell proliferation and the phosphorylation of downstream survival effectors of GH/GHR signaling in HepG2-SR tumor xenografts. H&E staining demonstrates that PEGV-200 treatment was associated with expanded areas of hemorrhage and tumor lysis (black circles) in HepG2 (left panel) and HepG2-SR (right panel) tumor xenografts. Admixed within these areas were small nests of residual tumor cells (black arrows). Immunohistochemical staining shows expression of GHR in tumor xenografts, however, Ki-67+ cells decreased remarkably in tumors from mice treated with PEGV-200 vs. those from control mice and mice treated with SOR-5 alone. The arrows highlight the small foci of residual tumor cells. In addition, pAKT, pERK, and pIGF-IR proteins were almost entirely lacking within the expanded areas of tumor hemorrhage and lysis and were limited only to scattered clusters of residual viable tumor cells in mice treated with PEGV-200 (arrows). Conversely, control tumors and tumors treated with SOR-5 alone showed high levels of expression of the activated forms of these survival proteins. Original magnification is x100 for H&E, Ki-67, and the SOR-5+PEGV-200 photomicrographs and x400 for all other photomicrographs.

References

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2017) 152(7):2557–76. doi: 10.1053/j.gastro.2007.04.061
2. Huizn-Melendez FD, Caparau M, O'Reilly EM, Duffy A, Gansukh B, Salta LL, et al. Advanced hepatocellular carcinoma: which staging systems best predict survival? J Clin Oncol (2010) 28(17):2889–95. doi: 10.1200/JCO.2009.25.9895
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 359(4):378–90. doi: 10.1056/NEJMoa0708857
4. Kudo M, Finn RS, Qin S, Han KH, Reda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (2018) 391(10126):1163–73. doi: 10.1016/S0140-6736(18)30207-1
5. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (2017) 389(10064):56–66. doi: 10.1016/S0140-6736(16)32453-9
6. Zhu AX, Park JO, Ryoo BY, Yoon CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicenter, phase 3 trial. Lancet Oncol (2015) 16(7):859–70. doi: 10.1016/S1470-2045(15)00056-9
7. Abu-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med (2018) 379(1):54–63. doi: 10.1056/NEJMoa1717002
8. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hussein C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet (2017) 389(10088):2492–502. doi: 10.1016/S0140-6736(17)31046-2
9. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol (2020) 38(3):193–202. doi: 10.1200/JCO.19.01307
Increased expression of growth hormone and prolactin receptors in hepatocellular carcinoma. J Hepatocell Carcinoma
Disruption of growth hormone receptor signaling abrogates hepatocellular carcinoma cells by STAT3 dependent inhibition of CLAUDIN-1
Hepatoscore-14: measures of biological heterogeneity signifying prediction of hepatocellular carcinoma risk. J Nat Cancer Int (2014) 1065(5):dj0888

Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, et al. Clinical and prognostic implications of plasma insulin-like growth factor-I and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol (2011) 29(29):3892–9. doi: 10.1200/JCO.2011.36.0636

Kaseb AO, Xiao L, Hassan MM, Chae YK, JS L, IN V, et al. Development and validation of insulin-like growth factor-I score to assess hepatic reserve in hepatocellular carcinoma. J Nat Cancer Int (2014) 1065(5):dj0888

29. Kaseb AO, Hassan MM, Siddiqui AM, Lin E, Xiao L, et al. Clinical and prognostic implications of plasma insulin-like growth factor-I and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol (2011) 29(29):3892–9. doi: 10.1200/JCO.2011.36.0636

30. van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 342(16):1171–7. doi: 10.1056/NEJM200008033421604

31. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 342(16):1171–7. doi: 10.1056/NEJM200008033421604

32. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 358(9295):1754–6. doi: 10.1016/S0140-6736(01)06844-1

33. Thompson BJ, Shan CA, Waters MJ. Identification of genes induced by growth hormone in rat liver using cDNA arrays. Endocrinology (2001) 141(11):4321–4. doi:10.1210/endo.141.11.7874

34. Iida K, Del Rincon JP, Kim DS, Itoh E, Nasr, Coschigano KT, et al. Tissue-specific regulation of growth hormone (GH) receptor and insulin-like growth factor-I gene expression in the pituitary and liver of GH-deficient (ile/ile) mice and transgenic mice that overexpress bovine GH (BGH) or a BGH antagonist. Endocrinology (2004) 145(4):1564–70. doi:10.1210/en.2003-1486

35. Miquet KJ, Gonzalez L, Matos MN, Hansen CE, Louis A, Bartke A, et al. Transgenic mice overexpressing GH exhibit hepatic upregulation of GH-signaling mediators involved in cell proliferation. J Endocrinol (2008) 198(2):317–30. doi:10.1677/JOE-08-00012

36. Pradhananga S, Wilkinson I, Ross BJ. Pegvisomant: structure and function. J Mol Endocrinol (2002) 29(1):11–4. doi:10.1677/jme.0.0290011

37. Ross BJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PFG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab (2001) 86(4):1716–23. doi:10.1210/clin Endocrinol Metab. 2001;86(4):1716–23. doi:10.1210/jcem.86.4.74403

38. Goffin V, Bernichete S, Carriere O, Bennett WF, Kopchick JJ, Kelly PA. The human growth hormone receptor B2036 does not interact with the prolactin receptor. Endocrinology (1999) 140(8):3853–6. doi:10.1210/endo.140.8.70404

39. Yin D, Vreeland F, Schaaf LJ, Millham RN, Duncan BA, Sharma A. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res (2007) 13(3):1000–9. doi:10.1158/1078-0432.CCR-06-1910

40. Dagnaes-Hansen F, Duan H, Rasmusson LM, Friend KE, Flyvbjerg A. Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res (2004) 24(6):3735–42.

41. Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat (2006) 98(3):315–27. doi:10.1007/s10549-006-1916-8

42. Evans A, Jamieson SM, Liu DX, Wilson WR, Perry JK. Growth hormone receptor antagonist suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model. Cancer Lett (2016) 379(1):117–23. doi:10.1016/j.clet.2016.05.031

43. McCutcheon IE, Flyvbjerg A, Hill H, Li J, Scarlett JL, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg (2002) 94(3):478–82. doi:10.3171/jns.2002.94.3.0487

COPYRIGHT © 2022 Kaseb, Haque, Vishwashmitra, Hassan, Xiao, George, Sahu, Mohamed, Carmagnani Pestana, Lombardo, Avritscher, Yao, Wolff, Rashid, Morris and Amin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
## Glossary

| Abbreviation | Definition |
|--------------|------------|
| AFP          | Alpha-fetoprotein |
| AKT          | Ak strain transforming |
| ANOVA        | analysis of variance |
| ATCC         | American Type Culture Collection |
| BCL-xS/L     | B-cell lymphoma-extra small/large |
| BCLC         | Barcelona Clinic Liver Cancer |
| BrdU         | bromodeoxyuridine |
| CI           | confidence interval |
| CLIP         | Cancer of the Liver Italian Program |
| c-Myc        | cellular myelocytomatosis virus |
| DMEM         | Dulbecco’s modified Eagle medium |
| DMSO         | dimethyl sulfoxide |
| EGFR         | epidermal growth factor receptor |
| ELISA        | enzyme-linked immunosorbent assay |
| ECM          | extracellular matrix |
| ERK          | extracellular signal-regulated kinase |
| FDA          | Food and Drug Administration |
| GH           | growth hormone |
| GHR          | growth hormone receptor |
| H            | high |
| HCC          | hepatocellular carcinoma |
| HepG2-SR     | sorafenib-resistant HepG2 cells |
| HR           | hazard ratio |
| hrGH         | human recombinant growth hormone |
| IGF-1        | type 1 insulin-like growth factor |
| IGF-IR       | type 1 insulin-like growth factor receptor |
| IRS-1        | insulin receptor substrate 1 |
| JAK2         | Janus kinase 2 |
| OS           | overall survival |
| MAP kinase   | mitogen-activated protein kinase |
| MCL-1        | myeloid cell leukemia 1 |
| mTOR         | mammalian target of rapamycin |
| N            | normal |
| No.          | number of patients |
| PBS          | phosphate buffered saline |
| PD-L1        | programmed cell death-ligand 1 |
| PEGV         | pegvisomant |
| PFS          | progression-free survival |
| PVTT         | portal vein tumor thrombus |
| RPMI         | Roswell Park Memorial Institute |
| siRNA        | small interfering RNA |
| SOR          | sorafenib |
| STAT         | signal transducer and activator of transcription |
| TKI          | tyrosine kinase inhibitor |
| TNM          | tumor size, number of lymph nodes, and presence of metastases |
| VEGF         | vascular endothelial growth factor |